Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

34.46 +3.43 (+11.05%)

Official Closing Price Updated: 4:15 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,666,034
Open	32.60
Bid (Size)	34.24 (700)
Ask (Size)	34.35 (4,300)
Prev. Close	31.03
Today's Range	32.50 - 35.73
52wk Range	18.92 - 43.15
Shares Outstanding	99,581,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

Today 14:13 EST

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Via MarketMinute

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

Today 13:03 EST

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Via The Motley Fool

Performance

YTD	-2.7%	-2.7%
1 Month	+7.0%	+7.0%
3 Month	-0.5%	-0.5%
6 Month	+33.3%	+33.3%
1 Year	+18.0%	+18.0%

More News

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

Today 10:09 EST

Via MarketMinute

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗

February 03, 2026

Via Stocktwits

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

Today 10:07 EST

Via MarketMinute

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

Today 5:30 EST

Via The Motley Fool

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

Via The Motley Fool

Is Viking Therapeutics Stock Really Going to $125? ↗

February 19, 2026

Via The Motley Fool

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

Via MarketMinute

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Via The Motley Fool

The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge

February 13, 2026

Via MarketMinute

Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes

February 13, 2026

Via MarketMinute

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

February 12, 2026

Via Stocktwits

Viking Therapeutics Stock Soars: What's Driving The Momentum? ↗

February 12, 2026

Via Benzinga

Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗

February 12, 2026

Via Stocktwits

Viking (VKTX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Via The Motley Fool

Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours ↗

February 11, 2026

Via Stocktwits

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

Via Stocktwits

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

Via The Motley Fool

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

Via The Motley Fool

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

Via The Motley Fool

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

February 07, 2026

Via The Motley Fool

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Via MarketMinute

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

Via MarketMinute

The Smartest Growth Stock to Buy With $30 Right Now ↗

February 03, 2026

Via The Motley Fool

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?

Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Viking Therapeutics, Inc. - Common Stock trade on?

Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?

The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market

What is the current price of Viking Therapeutics, Inc. - Common Stock?

The current price of Viking Therapeutics, Inc. - Common Stock is 34.46

When was Viking Therapeutics, Inc. - Common Stock last traded?

The last trade of Viking Therapeutics, Inc. - Common Stock was at 02/23/26 04:15 PM ET

What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?

The market capitalization of Viking Therapeutics, Inc. - Common Stock is 3.43B

How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?

Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.